NF-κB and therapeutic approach

Biomolecules and Therapeutics

Volumn 17, Issue 3, 2009, Pages 219-240

  Lee, Chang Hoon ^a   Kim, Soo Youl ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cancer; IKK ; Inflammation; NF B; NF B inhibitor; Transglutaminase 2

Indexed keywords

1 [5 HYDROXY 2 (2 THIENYL) 4 QUINAZOLINYLAMINO] 3 METHYL 2,5 PYRROLEDIONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABIN 1; ACYLTRANSFERASE INHIBITOR; BORTEZOMIB; BOT 64; BUTYRIC ACID; CARFILZOMIB; CISPLATIN; CP 1158; DACTINOMYCIN; DAUNORUBICIN; DEGUELIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GS 143; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMD 0560; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; IRINOTECAN; KCC 009; KINK 1; NSC 676914; PACLITAXEL; PF 184; PHA 408; PMX 464; PRISTIMERIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RETINOIC ACID INDUCIBLE PROTEIN I; SH 5; TACROLIMUS; TAUTOMYCETIN; TOLL LIKE RECEPTOR; TPCA 1; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VITAMIN K GROUP; VORINOSTAT; WDR 34; ZM 39923; ZM 449829;

DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

MUS;

EID: 69549116528     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2009.17.3.219     Document Type: Review

References (139)

1. Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z. W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J. and Karin, M. (2005). IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191-198. (Pubitemid 40321355)
2. Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., Gottlieb, E. and Vousden, K. H. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120. (Pubitemid 44040989)
3. Birrell, M. A., Hardaker, E., Wong, S., McCluskie, K., Catley, M., De Alba, J., Newton, R., Haj-Yahia, S., Pun, K. T., Watts, C. J., Shaw, R. J., Savage, T. J. and Belvisi, M. G. (2005). Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am. J. Respir. Crit. Care. Med. 172, 962-971. (Pubitemid 41476532)
4. Bonetti, B., Stegagno, C., Cannella, B., Rizzuto, N., Moretto, G. and Raine, C. S. (1999). Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am. J. Pathol. 155, 1433-1438.
5. Boone, D. L., Turer, E. E., Lee, E. G., Ahmad, R. C., Wheeler, M. T., Tsui, C., Hurley, P., Chien, M., Chai, S., Hitotsumatsu, O., McNally, E., Pickart, C. and Ma, A. (2004). The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5, 1052-1060. (Pubitemid 41057725)
6. Bottero, V., Busuttil, V., Loubat, A., Magne, N., Fischel, J. L., Milano, G. and Peyron, J. F. (2001). Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 61, 7785-7791. (Pubitemid 33049365)
7. Callister, M. E., Pinhu, L., Catley, M. C., Westwell, A. D., Newton, R., Leaver, S. K., Quinlan, G. J., Evans, T. W., Griffiths, M. J. and Burke-Gaffney, A. (2008). PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kappaB-dependent proinflammatory activation of alveolar epithelial cells. Br. J. Pharmacol. 155, 661-672.
8. Chica, R. A., Gagnon, P., Keillor, J. W. and Pelletier, J. N. (2004). Tissue transglutaminase acylation: Proposed role of conserved active site Tyr and Trp residues revealed by molecular modeling of peptide substrate binding. Protein Sci. 13, 979-991. (Pubitemid 38429221)
9. Choi, K., Siegel, M., Piper, J. L., Yuan, L., Cho, E., Strnad, P., Omary, B., Rich, K. M. and Khosla, C. (2005). Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem. Biol. 12, 469-475. (Pubitemid 40588922)
10. Choi, J. Y., Gao, W., Odegard, J., Shiah, H. S., Kashgarian, M., McNiff, J. M., Baker, D. C., Cheng, Y. C. and Craft, J. (2006a). Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis. Rheum. 54, 3277-3283. (Pubitemid 44622098)
11. Choi, S. H., Park, K. J., Ahn, B. Y., Jung, G., Lai, M. M. and Hwang, S. B. (2006b). Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase. Mol. Cell Biol. 26, 3048-3059.
12. Chun, J. K., Seo, D. W., Ahn, S. H., Park, J. H., You, J. S., Lee, C. H., Lee, J. C., Kim, Y. K. and Han, J. W. (2007). Suppression of the NF-kappaB signalling pathway by ergolide, sesquiterpene lactone, in HeLa cells. J. Pharm. Pharmacol. 59, 561-566.
13. Collier-Hyams, L. S., Zeng, H., Sun, J., Tomlinson, A. D., Bao, Z. Q., Chen, H., Madara, J. L., Orth, K. and Neish, A. S. (2002). Cutting edge: Salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-kappa B pathway. J. Immunol. 169, 2846-2850. (Pubitemid 35013124)
14. Dat, N. T., Lee, J. H., Lee, K., Hong, Y. S., Kim, Y. H. and Lee, J. J. (2008). Phenolic constituents of Amorpha fruticosa that inhibit NF-kappaB activation and related gene expression. J. Nat. Prod. 71, 1696-1700.
15. Dave, S. H., Tilstra, J. S., Matsuoka, K., Li, F., Karrasch, T., Uno, J. K., Sepulveda, A. R., Jobin, C., Baldwin, A. S., Robbins, P. D. and Plevy, S. E. (2007). Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J. Immunol. 179, 7852-7859.
16. de Macedo, P., Marrano, C. and Keillor, J. W. (2002). Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg. Med. Chem. 10, 355-360. (Pubitemid 33121260)
17. Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C. and Chen, Z. J. (2000). Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361.
18. Desmet, C., Gosset, P., Pajak, B., Cataldo, D., Bentires-Alj, M., Lekeux, P. and Bureau, F. (2004). Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J. Immunol. 173, 5766-5775. (Pubitemid 39392166)
19. Dey, A., Wong, E. T., Cheok, C. F., Tergaonkar, V. and Lane, D. P. (2008). R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 15, 263-273.
20. Dunne, A. and O'Neill, L. A. (2003). The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE 2003, re3.
21. Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. and Chen, Z. J. (2006). Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22, 245-257.
22. Edderkaoui, M., Odinokova, I., Ohno, I., Gukovsky, I., Go, V. L., Pandol, S. J. and Gukovskaya, A. S. (2008). Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J. Gastroenterol. 14, 3672-3680.
23. Ekbom, A. (1998). Risk of cancer in ulcerative colitis. J. Gastrointest. Surg. 2, 312-313.
24. Eldor, R., Yeffet, A., Baum, K., Doviner, V., Amar, D., Ben- Neriah, Y., Christofori, G., Peled, A., Carel, J. C., Boitard, C., Klein, T., Serup, P., Eizirik, D. L. and Melloul, D. (2006). Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc. Natl. Acad. Sci. USA 103, 5072-5077.
25. Fattovich, G., Stroffolini, T., Zagni, I. and Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127, S35-50. (Pubitemid 39423368)
26. Folk, J. E. and Cole, P. W. (1965). Structural requirements of specific substrates for guinea pig liver transglutaminase. J. Biol. Chem. 240, 2951-2960.
27. Folmer, F., Blasius, R., Morceau, F., Tabudravu, J., Dicato, M., Jaspars, M. and Diederich, M. (2006). Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem. Pharmacol. 71, 1206-1218. (Pubitemid 43357901)
28. Friedman, C. S., O'Donnell, M. A., Legarda-Addison, D., Ng, A., Cardenas, W. B., Yount, J. S., Moran, T. M., Basler, C. F., Komuro, A., Horvath, C. M., Xavier, R. and Ting, A. T. (2008). The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 9, 930-936.
29. Furusawa, J., Funakoshi-Tago, M., Tago, K., Mashino, T., Inoue, H., Sonoda, Y. and Kasahara, T. (2009). Licochalcone A significantly suppresses LPS signaling pathway through the inhibition of NF-kappaB p65 phosphorylation at serine 276. Cell Signal 21, 778-785.
30. Gagliardo, R., Chanez, P., Mathieu, M., Bruno, A., Costanzo, G., Gougat, C., Vachier, I., Bousquet, J., Bonsignore, G. and Vignola, A. M. (2003). Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am. J. Respir. Crit. Care Med. 168, 1190-1198. (Pubitemid 37424040)
31. Gao, D., Wang, R., Li, B., Yang, Y., Zhai, Z. and Chen, D. Y. (2009). WDR34 is a novel TAK1-associated suppressor of the IL-1R/TLR3/TLR4-induced NF-kappaB activation pathway. Cell Mol. Life Sci. Jun 12.
32. Gilmore, T. D. (1999). Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18, 6925-6937.
33. Gilmore, T. D. and Herscovitch, M. (2006). Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25, 6887-6899.
34. Gloire, G., Legrand-Poels, S. and Piette, J. (2006). NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 72, 1493-1505. (Pubitemid 44666727)
35. Griffin, M., Mongeot, A., Collighan, R., Saint, R. E., Jones, R. A., Coutts, I. G. and Rathbone, D. L. (2008). Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg. Med. Chem. Lett. 18, 5559-5562.
36. Hafeez, B. B., Siddiqui, I. A., Asim, M., Malik, A., Afaq, F., Adhami, V. M., Saleem, M., Din, M. and Mukhtar, H. (2008). A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. Cancer Res. 68, 8564-8572.
37. Handel, M. L., McMorrow, L. B. and Gravallese, E. M. (1995). Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis. Rheum. 38, 1762-1770.
38. Hiscott, J., Nguyen, T. L., Arguello, M., Nakhaei, P. and Paz, S. (2006). Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 25, 6844-6867. (Pubitemid 44657856)
39. Hwang, D. M., Kundu, J. K., Shin, J. W., Lee, J. C., Lee, H. J. and Surh, Y. J. (2007). Cis-9,trans-11-conjugated linoleic acid down-regulates phorbol ester-induced NF-kappaB activation and subsequent COX-2 expression in hairless mouse skin by targeting IkappaB kinase and PI3K-Akt. Carcinogenesis. 28, 363-371.
40. Izmailova, E. S., Paz, N., Alencar, H., Chun, M., Schopf, L., Hepperle, M., Lane, J. H., Harriman, G., Xu, Y., Ocain, T., Weissleder, R., Mahmood, U., Healy, A. M. and Jaffee, B. (2007). Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis. Rheum. 56, 117-128. (Pubitemid 46106184)
41. Jin, M., Moon, T. C., Quan, Z., Lee, E., Kim, Y. K., Yang, J. H., Suh, S. J., Jeong, T. C., Lee, S. H., Kim, C. H. and Chang, H. W. (2008). The naturally occurring flavolignan, deoxypodophyllotoxin, inhibits lipopolysaccharide- induced iNOS expression through the NF-kappaB activation in RAW264.7 macrophage cells. Biol. Pharm. Bull. 31, 1312-1315. (Pubitemid 351930638)
42. Jost, P. J. and Ruland, J. (2007). Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109, 2700-2707.
43. Kang, M. I., Henrich, C. J., Bokesch, H. R., Gustafson, K. R., McMahon, J. B., Baker, A. R., Young, M. R. and Colburn, N. H. (2009). A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits". Mol. Cancer Ther. 8, 571-581.
44. Karin, M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436.
45. Karin, M. (2008). The IkappaB kinase - a bridge between inflammation and cancer. Cell Res. 18, 334-342.
46. Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W. J., Van Wier, S., Tiedemann, R., Shi, C. X., Sebag, M., Braggio, E., Henry, T., Zhu, Y. X., Fogle, H., Price-Troska, T., Ahmann, G., Mancini, C., Brents, L. A., Kumar, S., Greipp, P., Dispenzieri, A., Bryant, B., Mulligan, G., Bruhn, L., Barrett, M., Valdez, R., Trent, J., Stewart, A. K., Carpten, J. and Bergsagel, P. L. (2007). Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131-144. (Pubitemid 47208626)
47. Kim, B. H., Lee, Y. G., Park, T. Y., Kim, H. B., Rhee, M. H. and Cho, J. Y. (2009a). Ginsenoside Rp1, a ginsenoside derivative, blocks lipopolysaccharide-induced interleukin-1beta production via suppression of the NF-kappaB pathway. Planta. Med. 75, 321-326.
48. Kim, B. H., Roh, E., Lee, H. Y., Lee, I. J., Ahn, B., Jung, S. H., Lee, H., Han, S. B. and Kim, Y. (2008a). Benzoxathiole derivative blocks lipopolysaccharide-induced nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene transcription through inactivating inhibitory kappaB kinase beta. Mol. Pharmacol. 73, 1309-1318.
49. Kim, B. H., Hong, S. S., Kwon, S. W., Lee, H. Y., Sung, H., Lee, I. J., Hwang, B. Y., Song, S., Lee, C. K., Chung, D., Ahn, B., Nam, S. Y., Han, S. B. and Kim, Y. (2008b). Diarctigenin, a lignan constituent from Arctium lappa, down-regulated zymosan-induced transcription of inflammatory genes through suppression of DNA binding ability of nuclear factor-kappaB in macrophages. J. Pharmacol. Exp. Ther. 327, 393-401.
50. Kim, B. H., Lee, J. Y., Seo, J. H., Lee, H. Y., Ryu, S. Y., Ahn, B. W., Lee, C. K., Hwang, B. Y., Han, S. B. and Kim, Y. (2007). Artemisolide is a typical inhibitor of IkappaB kinase beta targeting cysteine-179 residue and down-regulates NF-kappaB- dependent TNF-alpha expression in LPS-activated macrophages. Biochem. Biophys. Res. Commun. 361, 593-598.
51. Kim, B. H., Lee, K. H., Chung, E. Y., Chang, Y. S., Lee, H., Lee, C. K., Min, K. R. and Kim, Y. (2006a). Inhibitory effect of chroman carboxamide on interleukin-6 expression in response to lipopolysaccharide by preventing nuclear factor-kappaB activation in macrophages. Eur. J. Pharmacol. 543, 158-165. (Pubitemid 44092690)
52. Kim, D. S., Park, K. S., Jeong, K. C., Lee, B. I., Lee, C. H. and Kim, S. Y. (2009b). Glucosamine is an effective chemosensitizer via transglutaminase 2 inhibition. Cancer Lett. 273, 243-249.
53. Kim, D. S., Park, K. S. and Kim, S. Y. (2009c). Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors. Front Biosci. 14, 2514-2521.
54. Kim, D. S., Park, S. S., Nam, B. H., Kim, I. H. and Kim, S. Y. (2006b). Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 66, 10936-10943.
55. Kim, J. H., Lee, G., Cho, Y. L., Kim, C. K., Han, S., Lee, H., Choi, J. S., Choe, J., Won, M. H., Kwon, Y. G., Ha, K. S. and Kim, Y. M. (2009d). Desmethylanhydroicaritin inhibits NF-kappaB- regulated inflammatory gene expression by modulating the redox-sensitive PI3K/PTEN/Akt pathway. Eur. J. Pharmacol. 602, 422-431.
56. Kim, J. M., Lee, D. H., Kim, J. S., Lee, J. Y., Park, H. G., Kim, Y. J., Oh, Y. K., Jung, H. C. and Kim, S. I. (2009e). 5,7- dihydroxy-3,4,6- trimethoxyflavone inhibits the inflammatory effects induced by Bacteroides fragilis enterotoxin via dissociating the complex of heat shock protein 90 and I kappaB alpha and I kappaB kinase-gamma in intestinal epithelial cell culture. Clin. Exp. Immunol. 155, 541-551.
57. Kim, J. M., Voll, R. E., Ko, C., Kim, D. S., Park, K. S. and Kim, S. Y. (2008c). A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells. J. Mol. Biol. 384, 756-765.
58. Kim, J. W., Kim, B. G., Lee, K. L., Jeong, J. B., Jung, Y. J., Kim, J. S., Jung, H. C. and Song, I. S. (2008d). The effects of DA-6034 on NF-kappaB activity induced by lipopolysaccharide or tumor necrosis factor alpha in a human colonic epithelial cell line. Hepatogastroenterology 55, 2059-2064.
59. Kim, J. Y., Park, S. J., Yun, K. J., Cho, Y. W., Park, H. J. and Lee, K.T. (2008e). Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur. J. Pharmacol. 584, 175-184.
60. Kim, S. Y. (2006). Transglutaminase 2 in inflammation. Front Biosci. 11, 3026-3035.
61. Kondo, Y., Fukuda, K., Adachi, T. and Nishida, T. (2008). Inhibition by a selective IkappaB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture. Invest. Ophthalmol. Vis. Sci. 49, 4850-4857.
62. Krappmann, D. and Scheidereit, C. (2005). A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep. 6, 321-326. (Pubitemid 40561623)
63. Krikos, A., Laherty, C. D. and Dixit, V. M. (1992). Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J. Biol. Chem. 267, 17971-17976.
64. Ku, K. T., Huang, Y. L., Huang, Y. J. and Chiou, W. F. (2008). Miyabenol A inhibits LPS-induced NO production via IKK/ IkappaB inactivation in RAW 264.7 macrophages: possible involvement of the p38 and PI3K pathways. J. Agric. Food Chem. 56, 8911-8918.
65. Kuhn, D. J., Hunsucker, S. A., Chen, Q., Voorhees, P. M., Orlowski, M. and Orlowski, R. Z. (2009). Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113, 4667-4676.
66. Kuper, H., Adami, H. O. and Trichopoulos, D. (2000). Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171-183. (Pubitemid 30693788)
67. Kuroda, K., Horiguchi, Y., Nakashima, J., Kikuchi, E., Kanao, K., Miyajima, A., Ohigashi, T., Umezawa, K. and Murai, M. (2005). Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin. Cancer Res. 11, 5590-5594. (Pubitemid 41060837)
68. Kurylowicz, A. and Nauman, J. (2008). The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment. Acta. Biochim. Pol. 55, 629-647.
69. La Grutta, S., Gagliardo, R., Mirabella, F., Pajno, G. B., Bonsignore, G., Bousquet, J., Bellia, V. and Vignola, A. M. (2003). Clinical and biological heterogeneity in children with moderate asthma. Am. J. Respir. Crit. Care Med. 167, 1490-1495. (Pubitemid 37363357)
70. Lai, T. S., Liu, Y., Tucker, T., Daniel, K. R., Sane, D. C., Toone, E., Burke, J. R., Strittmatter, W. J. and Greenberg, C. S. (2008). Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem. Biol. 15, 969-978.
71. Le Negrate, G., Krieg, A., Faustin, B., Loeffler, M., Godzik, A., Krajewski, S. and Reed, J. C. (2008). ChlaDub1 of Chlamydia trachomatis suppresses NF-kappaB activation and inhibits IkappaBalpha ubiquitination and degradation. Cell Microbiol. 10, 1879-1892.
72. Lee, E. G., Boone, D. L., Chai, S., Libby, S. L., Chien, M., Lodolce, J. P. and Ma, A. (2000). Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289, 2350-2354. (Pubitemid 30739739)
73. Lee, G., Na, H. J., Namkoong, S., Jeong Kwon, H., Han, S., Ha, K. S., Kwon, Y. G., Lee, H. and Kim, Y. M. (2006a). 4-O-methylgallic acid down-regulates endothelial adhesion molecule expression by inhibiting NF-kappaB-DNA-binding activity. Eur. J. Pharmacol. 551, 143-151. (Pubitemid 44648048)
74. Lee, J., Kim, Y. S., Choi, D. H., Bang, M. S., Han, T. R., Joh, T. H. and Kim, S. Y. (2004). Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 279, 53725-53735. (Pubitemid 40051881)
75. Lee, J. C., Kundu, J. K., Hwang, D. M., Na, H. K. and Surh, Y. J. (2007a). Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-kappaB and AP-1: IkappaB kinase and c-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis 28, 1491-1498.
76. Lee, J. C., Won, S. J., Chao, C. L., Wu, F. L., Liu, H. S., Ling, P., Lin, C. N. and Su, C. L. (2008). Morusin induces apoptosis and suppresses NF-kappaB activity in human colorectal cancer HT-29 cells. Biochem. Biophys. Res. Commun. 372, 236-242.
77. Lee, J. S., Kim, I. H. and Kim, S. Y. (2006b). Changes in gene expression with increased transglutaminase 2 in a SH-SY5Y cell line. Front Biosci. 11, 2774-2781. (Pubitemid 43806579)
78. Lee, J. Y., Kim, J. S., Kim, J. M., Kim, N., Jung, H. C. and Song, I. S. (2007b). Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int. Immunopharmacol 7, 241-248. (Pubitemid 46037564)
79. Lewis, B. C., Klimstra, D. S., Socci, N. D., Xu, S., Koutcher, J. A. and Varmus, H. E. (2005). The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol. Cell Biol. 25, 1228-1237. (Pubitemid 40204903)
80. Lorand, L. and Graham, R. M. (2003). Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140-156. (Pubitemid 36172696)
81. Lounnas, N., Frelin, C., Gonthier, N., Colosetti, P., Sirvent, A., Cassuto, J. P., Berthier, F., Sirvent, N., Rousselot, P., Dreano, M., Peyron, J. F. and Imbert, V. (2009). NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int. J. Cancer 125, 308-317.
82. Maeda, S., Kamata, H., Luo, J. L., Leffert, H. and Karin, M. (2005). IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990. (Pubitemid 40884391)
83. Manam, R. R., Macherla, V. R., Tsueng, G., Dring, C. W., Weiss, J., Neuteboom, S. T., Lam, K. S. and Potts, B. C. (2009). Antiprotealide Is a Natural Product. J. Nat. Prod. 72, 295-297.
84. Matoba, S., Kang, J. G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F. and Hwang, P. M. (2006). p53 regulates mitochondrial respiration. Science 312, 1650-1653.
85. Mauro, C., Pacifico, F., Lavorgna, A., Mellone, S., Iannetti, A., Acquaviva, R., Formisano, S., Vito, P. and Leonardi, A. (2006). ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J. Biol. Chem. 281, 18482-18488. (Pubitemid 44035507)
86. May, M. J., D'Acquisto, F., Madge, L. A., Glockner, J., Pober, J. S. and Ghosh, S. (2000). Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289, 1550-1554. (Pubitemid 30677473)
87. Mbalaviele, G., Sommers, C. D., Bonar, S. L., Mathialagan, S., Schindler, J. F., Guzova, J. A., Shaffer, A. F., Melton, M. A., Christine, L. J., Tripp, C. S., Chiang, P. C., Thompson, D. C., Hu, Y. and Kishore, N. (2009). A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models. J. Pharmacol. Exp. Ther. 329, 14-25.
88. Meyer, S., Kohler, N. G. and Joly, A. (1997). Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett. 413, 354-358. (Pubitemid 27353299)
89. Miagkov, A. V., Kovalenko, D. V., Brown, C. E., Didsbury, J. R., Cogswell, J. P., Stimpson, S. A., Baldwin, A. S. and Makarov, S. S. (1998). NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA 95, 13859-13864.
90. Mitsuhashi, S., Shima, H., Li, Y., Tanuma, N., Okamoto, T., Kikuchi, K. and Ubukata, M. (2008). Tautomycetin suppresses the TNFalpha/NF-kappaB pathway via inhibition of IKK activation. Int. J. Oncol. 33, 1027-1035.
91. Mora, A. L., LaVoy, J., McKean, M., Stecenko, A., Brigham, K. L., Parker, R. and Rojas, M. (2005). Prevention of NF-kappaB activation in vivo by a cell-permeable NF-kappaB inhibitor peptide. Am. J. Physiol. Lung. Cell. Mol. Physiol. 289, L536-544. (Pubitemid 41361663)
92. Mosialos, G. (1997). The role of Rel/NF-kappa B proteins in viral oncogenesis and the regulation of viral transcription. Semin. Cancer. Biol. 8, 121-129. (Pubitemid 27412328)
93. Moussaieff, A., Shohami, E., Kashman, Y., Fride, E., Schmitz, M. L., Renner, F., Fiebich, B. L., Munoz, E., Ben-Neriah, Y. and Mechoulam, R. (2007). Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol. Pharmacol. 72, 1657-1664. (Pubitemid 350146103)
94. Nakajima, H., Fujiwara, H., Furuichi, Y., Tanaka, K. and Shimbara, N. (2008). A novel small-molecule inhibitor of NF-kappaB signaling. Biochem. Biophys. Res. Commun. 368, 1007-1013.
95. Nichols, D. B. and Shisler, J. L. (2006). The MC160 protein expressed by the dermatotropic poxvirus molluscum contagiosum virus prevents tumor necrosis factor alpha-induced NF-kappaB activation via inhibition of I kappa kinase complex formation. J. Virol. 80, 578-586.
96. Nishiyama, S., Manabe, N., Kubota, Y., Ohnishi, H., Kitanaka, A., Tokuda, M., Taminato, T., Ishida, T., Takahara, J. and Tanaka, T. (2005). Cyclosporin A inhibits the early phase of NF-kappaB/RelA activation induced by CD28 costimulatory signaling to reduce the IL-2 expression in human peripheral T cells. Int. Immunopharmacol. 5, 699-710. (Pubitemid 40248325)
97. Nurmi, A., Lindsberg, P. J., Koistinaho, M., Zhang, W., Juettler, E., Karjalainen-Lindsberg, M. L., Weih, F., Frank, N., Schwaninger, M. and Koistinaho, J. (2004). Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke 35, 987-991. (Pubitemid 38419815)
98. Pahan, K. and Schmid, M. (2000). Activation of nuclear factor-kB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett. 287, 17-20. (Pubitemid 30332367)
99. Pan, M. H., Lai, C. S., Wang, Y. J. and Ho, C. T. (2006). Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice. Biochem. Pharmacol. 72, 1293-1303.
100. Pan, M. R., Chang, H. C., Wu, Y. C., Huang, C. C. and Hung, W.C. (2009). Tubocapsanolide A inhibits transforming growth factor-beta-activating kinase 1 to suppress NF-kappaB- induced CCR7. J. Biol. Chem. 284, 2746-2754.
101. Pandey, M. K., Sung, B., Ahn, K. S., Kunnumakkara, A. B., Chaturvedi, M. M. and Aggarwal, B. B. (2007). Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 110, 3517-3525. (Pubitemid 350159615)
102. Pardin, C., Pelletier, J. N., Lubell, W. D. and Keillor, J. W. (2008). Cinnamoyl inhibitors of tissue transglutaminase. J. Org. Chem. 73, 5766-5775.
103. Park, S. S., Kim, J. M., Kim, D. S., Kim, I. H. and Kim, S. Y. (2006). Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster. J. Biol. Chem. 281, 34965-34972.
104. Pomerantz, J. L. and Baltimore, D. (2002). Two pathways to NF-kappaB. Mol. Cell. 10, 693-695.
105. Rajapakse, N., Kim, M. M., Mendis, E. and Kim, S. K. (2008). Inhibition of inducible nitric oxide synthase and cyclooxygenase- 2 in lipopolysaccharide- stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling. Immunology 123, 348-357. (Pubitemid 351171187)
106. Rawlings, D. J., Sommer, K. and Moreno-Garcia, M. E. (2006). The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol. 6, 799-812. (Pubitemid 44631649)
107. Roder, D. M. (2002). The epidemiology of gastric cancer. Gastric Cancer 5(Suppl 1), 5-11.
108. Saha, S. K., Pietras, E. M., He, J. Q., Kang, J. R., Liu, S. Y., Oganesyan, G., Shahangian, A., Zarnegar, B., Shiba, T. L., Wang, Y. and Cheng, G. (2006). Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. Embo. J. 25, 3257-3263. (Pubitemid 44141784)
109. Sanchez-Duffhues, G., Calzado, M. A., de Vinuesa, A. G., Appendino, G., Fiebich, B. L., Loock, U., Lefarth-Risse, A., Krohn, K. and Munoz, E. (2009). Denbinobin inhibits nuclear factor-kappaB and induces apoptosis via reactive oxygen species generation in human leukemic cells. Biochem. Pharmacol. 77, 1401-1409.
110. Schesser, K., Spiik, A. K., Dukuzumuremyi, J. M., Neurath, M. F., Pettersson, S. and Wolf-Watz, H. (1998). The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity. Mol. Microbiol. 28, 1067-1079. (Pubitemid 28293533)
111. Schon, M., Wienrich, B. G., Kneitz, S., Sennefelder, H., Amschler, K., Vohringer, V., Weber, O., Stiewe, T., Ziegelbauer, K. and Schon, M. P. (2008). KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J. Natl. Cancer Inst. 100, 862-875. (Pubitemid 351881954)
112. Sethi, G., Ahn, K. S., Sung, B. and Aggarwal, B. B. (2008a). Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol. Cancer Ther. 7, 1604-1614.
113. Sethi, G., Ahn, K. S., Sung, B., Kunnumakkara, A. B., Chaturvedi, M. M. and Aggarwal, B. B. (2008b). SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkappaBalpha kinase activation. Biochem. Pharmacol. 76, 1404-1416.
114. Shrestha, S., Bhattarai, B. R., Cho, H. and Choi, J. K. (2007). PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta). Bioorg. Med. Chem. Lett. 17, 2728-2730. (Pubitemid 46636263)
115. Siegel, M. and Khosla, C. (2007). Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol. Ther. 115, 232-245. (Pubitemid 47042912)
116. Siegel, M., Xia, J. and Khosla, C. (2007). Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg. Med. Chem. 15, 6253-6261. (Pubitemid 47088951)
117. Sironi, L., Banfi, C., Brioschi, M., Gelosa, P., Guerrini, U., Nobili, E., Gianella, A., Paoletti, R., Tremoli, E. and Cimino, M. (2006). Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiol. Dis. 22, 445-451.
118. Sohn, J., Kim, T. I., Yoon, Y. H., Kim, J. Y. and Kim, S. Y. (2003). Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J. Clin. Invest. 111, 121-128. (Pubitemid 36134855)
119. Strober, W., Murray, P. J., Kitani, A. and Watanabe, T. (2006). Signalling pathways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 6, 9-20. (Pubitemid 43279749)
120. Sommers, C. D., Thompson, J. M., Guzova, J. A., Bonar, S. L., Rader, R. K., Mathialagan, S., Venkatraman, N., Holway, V. W., Kahn, L. E., Hu, G., Garner, D. S., Huang, H. C., Chiang, P. C., Schindler, J. F., Hu, Y., Meyer, D. M. and Kishore, N. N. (2009). Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J. Pharmacol. Exp. Ther 330, 377-388.
121. Suh, G. Y., Ham, H. S., Lee, S. H., Choi, J. C., Koh, W. J., Kim, S. Y., Lee, J., Han, J., Kim, H. P., Choi, A. M. and Kwon, O. J. (2006). A peptide with anti-transglutaminase activity decreases lipopolysaccharide-induced lung inflammation in mice. Exp. Lung. Res. 32, 43-53. (Pubitemid 43732306)
122. Sun, L., Deng, L., Ea, C. K., Xia, Z. P. and Chen, Z. J. (2004). The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 14, 289-301. (Pubitemid 38591401)
123. Sung, B., Pandey, M. K. and Aggarwal, B. B. (2007). Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol. Pharmacol. 71, 1703-1714. (Pubitemid 47010923)
124. Tartaglia, L. A. and Goeddel, D. V. (1992). Two TNF receptors. Immunol. Today 13, 151-153.
125. Thorgeirsson, S. S. and Grisham, J. W. (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31, 339-346. (Pubitemid 35154440)
126. Tiedemann, R. E., Schmidt, J., Keats, J. J., Shi, C. X., Zhu, Y. X., Palmer, S. E., Mao, X., Schimmer, A. D. and Stewart, A. K. (2009). Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 113, 4027-4037.
127. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A. and Mosialos, G. (2003). CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793-796. (Pubitemid 37021710)
128. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., Flygare, J. A., Fairbrother, W. J., Deshayes, K., Dixit, V. M. and Vucic, D. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131, 669-681. (Pubitemid 350087204)
129. Venkataraman, L., Burakoff, S. J. and Sen, R. (1995). FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J. Exp. Med. 181, 1091-1099.
130. Wakatsuki, S., Suzuki, J., Ogawa, M., Masumura, M., Muto, S., Shimizu, T., Takayama, K., Itai, A. and Isobe, M. (2008). A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration. Expert. Opin. Ther. Targets 12, 1469-1476.
131. Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., Ma, A., Koonin, E. V. and Dixit, V. M. (2004). De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694-699. (Pubitemid 39061687)
132. Wu, C. J. and Ashwell, J. D. (2008). NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. USA 105, 3023-3028.
133. Wu, Z. H., Shi, Y., Tibbetts, R. S. and Miyamoto, S. (2006). Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 311, 1141-1146. (Pubitemid 43305951)
134. Xiao, G., Cvijic, M. E., Fong, A., Harhaj, E. W., Uhlik, M. T., Waterfield, M. and Sun, S. C. (2001). Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. Embo. J. 20, 6805-6815. (Pubitemid 33134210)
135. Yan, S. S., Li, Y., Wang, Y., Shen, S. S., Gu, Y., Wang, H. B., Qin, G. W. and Yu, Q. (2008). 17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells. Mol. Cancer Ther. 7, 1523-1532.
136. Yanai, A., Maeda, S., Shibata, W., Hikiba, Y., Sakamoto, K., Nakagawa, H., Ohmae, T., Hirata, Y., Ogura, K., Muto, S., Itai, A. and Omata, M. (2008). Activation of IkappaB kinase and NF-kappaB is essential for Helicobacter pylori-induced chronic gastritis in Mongolian gerbils. Infect. Immun. 76, 781-787. (Pubitemid 351251751)
137. Yoneyama, M. and Fujita, T. (2008). Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 29, 178-181.
138. Yore, M. M., Liby, K. T., Honda, T., Gribble, G. W. and Sporn, M. B. (2006). The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28- oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol. Cancer Ther. 5, 3232-3239. (Pubitemid 46092066)
139. Zuckerman, S. H., Evans, G. F. and Guthrie, L. (1991). Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA. Immunology 73, 460-465.